Quantitative Ultrasound to Assess Steatotic Liver Disease in Children

NCT ID: NCT06706856

Last Updated: 2024-11-27

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

120 participants

Study Classification

OBSERVATIONAL

Study Start Date

2024-09-23

Study Completion Date

2029-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This research study is being conducted to find out more about advanced ultrasound techniques to non-invasively evaluate liver disease in children. The investigators are developing advanced techniques for analyzing ultrasound data and images of the liver, and they will compare it to other established methods used to evaluate the liver, including liver MRI.

The investigators plan to develop and test the advanced analysis techniques using conventional full-size ultrasound machines and, if possible, small handheld devices.

Our goals are:

* To assess the accuracy of the advanced ultrasound analysis techniques in children
* To implement and assess these advanced technique on small handheld ultrasound devices, if possible

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Our broad long-term objective is to improve the health of children with metabolic dysfunction-associated steatotic liver disease (MASLD), a condition characterized by accumulation of fat in liver cells, by developing and validating accurate, precise, practical, and widely available tools to detect, measure, and monitor liver fat.

Our study aims to develop advanced quantitative ultrasound (QUS) analysis models for use with full-size US and, if possible, inexpensive point-of-care ultrasound (POCUS) systems in children at risk for MASLD to estimate liver fat fraction and classify presence/absence of fatty liver. We anticipate the models will incorporate technical innovations to improve QUS accuracy and efficiency. To develop and test these models, we plan to enroll 120 children who will undergo ultrasound exams using either full-size or POCUS devices. We plan to compare the performance of our QUS models with liver MRI.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

MASLD MASLD - Metabolic Dysfunction-Associated Steatotic Liver Disease

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Cohort

This is a single arm study in which all participants undergo the same research procedures.

MR exam

Intervention Type DIAGNOSTIC_TEST

Participants will undergo an advanced magnetic resonance (MR) examination of the abdomen and liver.

US exam

Intervention Type DIAGNOSTIC_TEST

Participants will undergo an abdominal ultrasound (US) examination using a full-size US system. Some participants may undergo a point-of-care abdominal US exam with a handheld US system, if possible.

Blood draw

Intervention Type OTHER

Participants will undergo a blood draw of approximately 25 mL volume.

Physical measurements

Intervention Type OTHER

Participants will have their height, weight and waist circumference measured. Vital signs including respiratory frequency, heart rate, temperature, and blood pressure will be measured.

Questionnaires

Intervention Type OTHER

Participants will be asked to fill out questionnaires to collect information about their prescribed medications, demographics, medical and surgical histories, prior laboratory results, physical activity and lifestyle measures, and potential alcohol intake (AUDIT questionnaire).

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

MR exam

Participants will undergo an advanced magnetic resonance (MR) examination of the abdomen and liver.

Intervention Type DIAGNOSTIC_TEST

US exam

Participants will undergo an abdominal ultrasound (US) examination using a full-size US system. Some participants may undergo a point-of-care abdominal US exam with a handheld US system, if possible.

Intervention Type DIAGNOSTIC_TEST

Blood draw

Participants will undergo a blood draw of approximately 25 mL volume.

Intervention Type OTHER

Physical measurements

Participants will have their height, weight and waist circumference measured. Vital signs including respiratory frequency, heart rate, temperature, and blood pressure will be measured.

Intervention Type OTHER

Questionnaires

Participants will be asked to fill out questionnaires to collect information about their prescribed medications, demographics, medical and surgical histories, prior laboratory results, physical activity and lifestyle measures, and potential alcohol intake (AUDIT questionnaire).

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Age 9 to 18 years
* Presence of risk factors for having MASLD
* Ability and willingness of participant or legal guardian/parent to give written informed consent
* Participant is willing to give written assent
* Able and willing to undergo all study procedures

Exclusion Criteria

* Known liver disease other than MASLD
* Pregnant or trying to become pregnant
* Inability to undergo an MR study: weight exceeding scanner table limit, waist circumference \> 140 cm, claustrophobie, and/or metal implants.
Minimum Eligible Age

9 Years

Maximum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

NIH

Sponsor Role collaborator

Virginia Polytechnic Institute and State University

OTHER

Sponsor Role collaborator

GE Healthcare

INDUSTRY

Sponsor Role collaborator

University of California, San Diego

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Claude Sirlin

Professor of Radiology

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Jeffrey B Schwimmer, MD

Role: PRINCIPAL_INVESTIGATOR

University of California, San Diego

Claude B Sirlin, MD

Role: PRINCIPAL_INVESTIGATOR

University of California, San Diego

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

University of California San Diego

La Jolla, California, United States

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

United States

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Amy Alba

Role: CONTACT

619-543-5228

Gage Tanzman

Role: CONTACT

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Amy Alba

Role: primary

619-543-5226

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

1R01DK135951-01

Identifier Type: NIH

Identifier Source: secondary_id

View Link

809669

Identifier Type: -

Identifier Source: org_study_id